Optimising Antimicrobial Selection and Duration in the Treatment of Febrile Neutropenia in Children

References

• Arif T, Phillips RS. Updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment and management of fever during neutropenia in children with cancer. Pediatr Blood Cancer. 2019;66(10):e27887. doi:10.1002/pbc.2788731250539
   PubMed Web of Science ®Google Scholar
• Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018;320(10):995–1004. doi:10.1001/jama.2018.1251230208456
   PubMed Web of Science ®Google Scholar
• Haeusler GM, De Abreu Lourenco R, Clark H, et al. Diagnostic yield of initial and consecutive blood cultures in children with cancer and febrile neutropenia. J Pediatric Infect Dis Soc. 2020. doi:10.1093/jpids/piaa029
   Web of Science ®Google Scholar
• Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45(10):1296–1304. doi:10.1086/52253317968824
   PubMed Web of Science ®Google Scholar
• Herd F, Bate J, Chisholm J, Johnson E, Phillips B. Variation in practice remains in the UK management of paediatric febrile neutropenia. Arch Dis Child. 2016;101(4):410–411. doi:10.1136/archdischild-2015-31029426893520
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Slavin MA, Bryant PA, Babl FE, Mechinaud F, Thursky KA. Management of fever and neutropenia in children with cancer: a survey of Australian and New Zealand practice. J Paediatr Child Health. 2018;54(7):761–769. doi:10.1111/jpc.1389929655245
   PubMed Web of Science ®Google Scholar
• Duncan C, Chisholm JC, Freeman S, Riley U, Sharland M, Pritchard-Jones K. A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England. Pediatr Blood Cancer. 2007;49(5):678–681. doi:10.1002/pbc.2104117066460
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Thursky KA, Slavin MA, et al. Risk stratification in children with cancer and febrile neutropenia: a national, prospective, multicentre validation of nine clinical decision rules. EClinicalMedicine. 2020;18:100220. doi:10.1016/j.eclinm.2019.11.01331993576
   PubMedGoogle Scholar
• Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. JCO. 2017;35(18):2082–2094. doi:10.1200/JCO.2016.71.7017
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427–4438. doi:10.1200/JCO.2012.42.716122987086
   PubMed Web of Science ®Google Scholar
• Allaway Z, Phillips RS, Thursky KA, Haeusler GM. Nonneutropenic fever in children with cancer: a scoping review of management and outcome. Pediatr Blood Cancer. 2019;66(6):e27634. doi:10.1002/pbc.2763430724005
   PubMed Web of Science ®Google Scholar
• Morgan JE. Fifteen minute consultation: fever in children being treated for cancer. Arch Dis Child. 2019;104(3):124–128. doi:10.1136/archdischild-2017-31471829599167
   PubMed Web of Science ®Google Scholar
• Israels T, Renner L, Hendricks M, Hesseling P, Howard S, Molyneux E. SIOP PODC: recommendations for supportive care of children with cancer in a low-income setting. Pediatr Blood Cancer. 2013;60(6):899–904. doi:10.1002/pbc.2450123441092
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Phillips RS, Lehrnbecher T, Thursky KA, Sung L, Ammann RA. Core outcomes and definitions for pediatric fever and neutropenia research: a consensus statement from an international panel. Pediatr Blood Cancer. 2015;62(3):483–489. doi:10.1002/pbc.2533525446628
   PubMed Web of Science ®Google Scholar
• NICE. CG151 neutropenic sepsis: full guideline. NICE. Available from: http://www.nice.org.uk/. Accessed 925, 2013.
   Google Scholar
• Morgan JE, Phillips B. Winter 2017 children’s cancer and leukaemia group febrile neutropenia audit. Arch Dis Child. 2018;archdischild-2018-315249. doi:10.1136/archdischild-2018-315249
   Web of Science ®Google Scholar
• Koenig C, Bodmer N, Agyeman PKA, et al. 39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. Lancet Child Adolesc Health. 2020;4(7):495–502. doi:10.1016/S2352-4642(20)30092-432497520
   PubMedGoogle Scholar
• Rodríguez L, Ethier M-C, Phillips B, Lehrnbecher T, Doyle J, Sung L. Utility of peripheral blood cultures in patients with cancer and suspected blood stream infections: a systematic review. Support Care Cancer. 2012;20(12):3261–3267. doi:10.1007/s00520-012-1471-222544224
   PubMed Web of Science ®Google Scholar
• Feghaly REE, Chatterjee J, Dowdy K, et al. A quality improvement initiative: reducing blood culture contamination in a children’s hospital. Pediatrics. 2018;142(4):e20180244. doi:10.1542/peds.2018-024430217808
   PubMed Web of Science ®Google Scholar
• Stevenson M, Pandor A, James MS, et al. Sepsis: the LightCycler SeptiFast test MGRADE®, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation. Health Technol Assess (Rockv). 2016;20(46). doi:10.3310/hta20460
   Web of Science ®Google Scholar
• Guido M, Quattrocchi M, Zizza A. Molecular approaches in the diagnosis of sepsis in neutropenic patients with haematological malignances. J Prev Med Hyg. 2012;53(2):104–108.23240170
   PubMedGoogle Scholar
• Torres JP, De la Maza V, Kors L, et al. Respiratory viral infections and coinfections in children with cancer, fever and neutropenia: clinical outcome of infections caused by different respiratory viruses. Pediatr Infect Dis J. 2016;35(9):949–954. doi:10.1097/INF.000000000000120927518750
   PubMed Web of Science ®Google Scholar
• Santolaya ME, Alvarez AM, Acuña M, et al. Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical trial. Clin Microbiol Infect. 2017;23(3):173–178. doi:10.1016/j.cmi.2016.11.00127856269
   PubMed Web of Science ®Google Scholar
• Rosa R, Suarez JF, Bravo G, et al. Challenges in antimicrobial stewardship: rapid diagnostics and optimization of therapy among immunocompromised patients. Open Forum Infect Dis. 2019;6(7). doi:10.1093/ofid/ofz239
   Web of Science ®Google Scholar
• Buss BA, Baures TJ, Yoo M, et al. Impact of a multiplex PCR assay for bloodstream infections with and without antimicrobial stewardship intervention at a cancer hospital. Open Forum Infect Dis. 2018;5(10). doi:10.1093/ofid/ofy258
   Web of Science ®Google Scholar
• Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10(1):6. doi:10.1186/1741-7015-10-622257704
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Carlesse F, Phillips RS. An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J. 2013;32(10):e390–6. doi:10.1097/INF.0b013e31829ae38d23673421
   PubMed Web of Science ®Google Scholar
• Douglas AP, Thursky KA, Worth LJ, Harrison SJ, Hicks RJ, Slavin MA. FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. Leuk Lymphoma. 2019;60(10):2471–2476. doi:10.1080/10428194.2019.159057130947578
   PubMed Web of Science ®Google Scholar
• Douglas A, Lau E, Thursky K, Slavin M. What, where and why: exploring fluorodeoxyglucose-PET’s ability to localise and differentiate infection from cancer. Curr Opin Infect Dis. 2017;30(6):552–564. doi:10.1097/QCO.000000000000040528922285
   PubMed Web of Science ®Google Scholar
• Wang SS, Mechinaud F, Thursky K, Cain T, Lau E, Haeusler GM. The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children. J Paediatr Child Health. 2018;54(5):487–492. doi:10.1111/jpc.1380929235187
   PubMed Web of Science ®Google Scholar
• Fernández-Cruz A, Lewis RE, Kontoyiannis DP. How long do we need to treat an invasive mold disease in hematology patients? factors influencing duration of therapy and future questions. Clin Infect Dis. 2020;71(3):685–692. doi:10.1093/cid/ciz119532170948
   PubMed Web of Science ®Google Scholar
• Koh KC, Slavin MA, Thursky KA, et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. Leuk Lymphoma. 2012;53(10):1889–1895. doi:10.3109/10428194.2012.67753322448920
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Thursky KA, Slavin MA, et al. External validation of six pediatric fever and neutropenia clinical decision rules. Pediatr Infect Dis J. 2018;37(4):329–335. doi:10.1097/INF.000000000000177728877157
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Phillips R, Slavin MA, et al. Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia. EClinicalMedicine. 2020;23:100394. doi:10.1016/j.eclinm.2020.10039432637894
   PubMedGoogle Scholar
• Phillips B, Morgan JE, Haeusler GM, Riley RD, PICNICC Collaborative. Individual participant data validation of the PICNICC prediction model for febrile neutropenia. Arch Dis Child. 2020;105(5):439–445. doi:10.1136/archdischild-2019-31730831690548
   PubMed Web of Science ®Google Scholar
• Dommett R, Geary J, Freeman S, et al. Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting. Eur J Cancer. 2009;45(16):2843–2849. doi:10.1016/j.ejca.2009.06.00319616427
   PubMed Web of Science ®Google Scholar
• ISRCTN. ISRCTN13185152: Is It Practical to Perform a Study to Manage Antibiotic Delivery in Febrile Neutropenia for Children and Young People Undergoing Treatment with Anti-Cancer Drugs with the Routine Serial Use of PCT Measurements? 2020. doi:10.1186/ISRCTN13185152
   Google Scholar
• Haeusler GM, Sung L, Ammann RA, Phillips B. Management of fever and neutropenia in paediatric cancer patients: room for improvement? Curr Opin Infect Dis. 2015;28(6):532–538. doi:10.1097/QCO.000000000000020826381997
   PubMed Web of Science ®Google Scholar
• Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321–331. doi:10.1016/j.jinf.2013.12.00624370562
   PubMed Web of Science ®Google Scholar
• Vidal L, Dor IB, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev. 2013;(10). doi:10.1002/14651858.CD003992.pub3
   Web of Science ®Google Scholar
• Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37(3):382–389. doi:10.1086/37663712884163
   PubMed Web of Science ®Google Scholar
• Erjavec Z, de Vries-hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother. 2000;45(6):843–849. doi:10.1093/jac/45.6.84310837439
   PubMed Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72(1):101–111. doi:10.1016/0002-9343(82)90594-07058815
   PubMed Web of Science ®Google Scholar
• Mesini A, Carlesse F, Ammann R, et al. Proportions of antimicrobial resistant BSIs in children receiving antineoplastic chemotherapy (AC) or hemopoietic stem cell transplant (HSCT): preliminary results from an international multicenter study. In: 29th ECCMID; 2019. Abstract No 2054.
   Google Scholar
• Levene I, Castagnola E, Haeusler GM. Antibiotic-resistant gram-negative blood stream infections in children with cancer: a review of epidemiology, risk factors, and outcome. Pediatr Infect Dis J. 2018;37(5):495–498. doi:10.1097/INF.000000000000193829432384
   PubMed Web of Science ®Google Scholar
• Haeusler GM, Levene I. Question 2: what are the risk factors for antibiotic resistant gram-negative bacteraemia in children with cancer? Arch Dis Child. 2015;100(9):895–898. doi:10.1136/archdischild-2015-30917526194357
   PubMed Web of Science ®Google Scholar
• Pillinger KE, Bouchard J, Withers ST, et al. Inpatient antibiotic stewardship interventions in the adult oncology and hematopoietic stem cell transplant population: a review of the literature. Ann Pharmacother. 2020;54(6):594–610. doi:10.1177/106002801989088631771337
   PubMed Web of Science ®Google Scholar
• Messacar K, Parker SK, Todd JK, Dominguez SR, Kraft CS. Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. J Clin Microbiol. 2017;55(3):715–723. doi:10.1128/JCM.02264-1628031432
   PubMed Web of Science ®Google Scholar
• Hennig S, Staatz CE, Natanek D, et al. Antimicrobial stewardship in paediatric oncology: impact on optimising gentamicin use in febrile neutropenia. Pediatr Blood Cancer. 2018;65(2):e26810. doi:10.1002/pbc.26810
   Web of Science ®Google Scholar
• Santiago‐García B, Rincón‐López EM, Ponce Salas B, et al. Effect of an intervention to improve the prescription of antifungals in pediatric hematology-oncology. Pediatr Blood Cancer. 2020;67(4):e27963. doi:10.1002/pbc.2796331407514
   PubMed Web of Science ®Google Scholar
• Karandikar MV, Milliren CE, Zaboulian R, et al. Limiting vancomycin exposure in pediatric oncology patients with febrile neutropenia may be associated with decreased vancomycin-resistant enterococcus incidence. J Pediatric Infect Dis Soc. 2020;9(4):428–436. doi:10.1093/jpids/piz06431603472
   PubMed Web of Science ®Google Scholar
• Koenig C, Schneider C, Morgan JE, Ammann RA, Sung L, Phillips B. Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review. Support Care Cancer. 2020;28(3):1369–1383. doi:10.1007/s00520-019-04961-431264188
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118. doi:10.1093/annonc/mdw32527664247
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology and infectious diseases society of america clinical practice guideline update. J Clin Oncol. 2018;36(14):1443–1453. doi:10.1200/JCO.2017.77.621129461916
   PubMed Web of Science ®Google Scholar
• McCavit TL, Winick N. Time-to-antibiotic administration as a quality of care measure in children with febrile neutropenia: a survey of pediatric oncology centers. Pediatr Blood Cancer. 2012;58(2):303–305. doi:10.1002/pbc.2314821509930
   PubMed Web of Science ®Google Scholar
• Koenig C, Schneider C, Morgan JE, Ammann RA, Sung L, Phillips B. Interventions aiming to reduce time to antibiotics (TTA) in patients with fever and neutropenia during chemotherapy for cancer (FN), a systematic review. Support Care Cancer. 2020;28(5):2369–2380. doi:10.1007/s00520-019-05056-w31486984
   PubMed Web of Science ®Google Scholar
• Agyeman P, Kontny U, Nadal D, et al. A prospective multicenter study of microbiologically defined infections in pediatric cancer patients with fever and neutropenia: Swiss pediatric oncology group 2003 fever and neutropenia study. Pediatr Infect Dis J. 2014;33(9):e219–225. doi:10.1097/INF.000000000000032624618935
   PubMed Web of Science ®Google Scholar
• Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the second European conference on infections in leukemia. Bone Marrow Transplant. 2009;43(10):757–770. doi:10.1038/bmt.2008.38619043458
   PubMed Web of Science ®Google Scholar
• Ward KN, Hill JA, Hubacek P, et al. Guidelines from the 2017 European conference on infections in leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. Haematologica. 2019;104(11):2155–2163. doi:10.3324/haematol.2019.22307331467131
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European conference on infections in leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272. doi:10.1016/S1473-3099(19)30107-031153807
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14(6):555–563. doi:10.1111/tid.1202223146063
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56(2):258–266. doi:10.1093/cid/cis84423024295
   PubMed Web of Science ®Google Scholar
• Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis. 2013;15(3):219–232. doi:10.1111/tid.1205423363310
   PubMed Web of Science ®Google Scholar
• Fisher BT, Robinson PD, Lehrnbecher T, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review. J Pediatric Infect Dis Soc. 2018;7(3):191–198. doi:10.1093/jpids/pix03028549148
   PubMed Web of Science ®Google Scholar
• Morgan JE, Hassan H, Cockle JV, Lethaby C, James B, Phillips RS. Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. Support Care Cancer. 2016. doi:10.1007/s00520-016-3412-y
   Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15(8):e327–340. doi:10.1016/S1470-2045(14)70017-824988936
   PubMed Web of Science ®Google Scholar
• Egan G, Robinson PD, Martinez JPD, et al. Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: a systematic review of randomized trials. Cancer Med. 2019;8(10):4536–4546. doi:10.1002/cam4.239531274245
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. JCO. 2020;38(27):3205–3216. doi:10.1200/JCO.20.00158
   PubMed Web of Science ®Google Scholar
• Bate J, Baker S, Breuer J, et al. PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. Arch Dis Child. 2019;104(1):25–29. doi:10.1136/archdischild-2017-31421229730641
   PubMed Web of Science ®Google Scholar
• Proudfoot R, Cox R, Phillips B, Wilne S. Guidelines for the prophylaxis of pneumocystis jirovecii pneumonia (PJP) in children with solid tumours. Child Cancer Leukaemia Group. 2016;83.
   Google Scholar
• Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;2014(10). doi:10.1002/14651858.CD005590.pub3
   Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer; 1979. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/783/CN-00020783/frame.html. Accessed 925, 2013.
   Google Scholar
• Morgan JE, Cleminson J, Atkin K, Stewart LA, Phillips RS. Systematic review of reduced therapy regimens for children with low risk febrile neutropenia. Support Care Cancer. 2016;24(6):2651–2660. doi:10.1007/s00520-016-3074-926757936
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):427–431. doi:10.1093/cid/ciq14721205990
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98(12):1826–1835. doi:10.3324/haematol.2013.09102524323983
   PubMed Web of Science ®Google Scholar
• Stern A, Carrara E, Bitterman R, Yahav D, Leibovici L, Paul M. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst Rev. 2019;1:CD012184. doi:10.1002/14651858.CD012184.pub230605229
   PubMed Web of Science ®Google Scholar
• ISRCTN. ISRCTN11369832: Using Procalcitonin to Guide Duration of Antibiotics. 2017. doi:10.1186/ISRCTN11369832
   Google Scholar
• Haeusler GM, Gaynor L, Teh B, et al. Home-based care of low-risk febrile neutropenia in children-an implementation study in a tertiary paediatric hospital. Support Care Cancer. 2020;29(3):1609–1617. doi:10.1007/s00520-020-05654-z32740894
   PubMed Web of Science ®Google Scholar
• Mustafa MM, Aquino VM, Pappo A, Tkaczewski I, Buchanan GR. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr. 1996;128(6):847–849. doi:10.1016/S0022-3476(96)70339-68648546
   PubMed Web of Science ®Google Scholar
• Teuffel O, Amir E, Alibhai SMH, Beyene J, Sung L. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics. 2011;127(2):e279–286. doi:10.1542/peds.2010-073421220399
   PubMed Web of Science ®Google Scholar
• Orme L, Babl F, Barnes C, Barnett P, Donath S, Ashley D. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial. Pediatr Blood Cancer. 2014;61(8):1427–1433. doi:10.1002/pbc.2501224604835
   PubMed Web of Science ®Google Scholar
• Morgan JE, Phillips B, Stewart LA, Atkin K. Quest for certainty regarding early discharge in paediatric low-risk febrile neutropenia: a multicentre qualitative focus group discussion study involving patients, parents and healthcare professionals in the UK. BMJ Open. 2018;8(5):e020324. doi:10.1136/bmjopen-2017-020324
   Web of Science ®Google Scholar
• Phillips B, Morgan JE. Meta-analytic validation of new ‘AUS’ febrile neutropenia risk score. Pediatr Blood Cancer. 2021;e28580. doi:10.1002/pbc.2858032710695
   PubMed Web of Science ®Google Scholar